ClinicalTrials.gg
Active, not recruitingNCT05888922Updated Nov 2, 2026

Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

A Phase 3 interventional study of Minoxidil Tablets and Minoxidil Topical in Androgenetic Alopecia and Female Pattern Baldness, sponsored by Industrial Farmacéutica Cantabria, S.A.. Active, not recruiting at 27 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Industrial Farmacéutica Cantabria, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Planned enrollment
Largest of 31
520 · median 60
Started
2024
with 1 other
Phase 3
8 of 31
2 open now
Primary completion
2026-10
later than 6 of 11 live
Registered
20th of 31
by date
Lead sponsor
1 of 31
Industrial Farmacéutica Cantabria, S.A.

Among the 31 studies testing minoxidil in Alopecia, this one has the largest planned enrollment, is one of 2 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 6 of the 11 other live ones, and was the 20th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

This phase III clinical trial is evaluating whether oral minoxidil 1 mg is an effective and safe treatment for women with androgenetic alopecia (female pattern hair loss).

Approximately 520 women is planned to take part in the study. Participants will be randomly assigned to receive either oral minoxidil, topical minoxidil 2% solution, or placebo. Neither the participants nor the study staff will know which treatment has been assigned.

The study will last up to 36 weeks, including a treatment period of 24 weeks and a follow-up period. Participants will attend regular study visits to assess hair growth and monitor safety.

Site investigators will evaluate changes in hair growth and hair density using scalp imaging, investigator assessments, and participant questionnaires. Safety will be monitored through physical examinations, vital signs, laboratory tests, electrocardiograms, and the recording of side effects throughout the study.

Read the detailed description

This Phase III, multicenter, randomized, double-blind, placebo- and active-controlled study will evaluate the efficacy and safety of oral minoxidil 1 mg in approximately 520 adult women with female androgenetic alopecia (Sinclair grade 2-4), enrolled across study sites in Germany, Spain, Italy, and Portugal. Participants will be randomized in a 2:2:1 ratio to receive oral minoxidil plus topical vehicle, topical minoxidil 2% plus oral placebo, or double placebo.

The study includes a screening period of up to 8 weeks, a 24-week treatment period, and a 4-week follow-up period, with approximately 10 scheduled visits. Study treatment will consist of once-daily oral administration and twice-daily topical application. The first treatment administration will be supervised at the study site, followed by self-administration at home, with treatment compliance recorded in an electronic diary.

Efficacy will be evaluated using quantitative target area hair measurements, including non-vellus hair count, hair density, and hair width, assessed through digital image analysis. Additional efficacy assessments will include investigator global evaluations based on standardized scalp photography and patient-reported quality-of-life questionnaires.

Safety assessments will include physical examinations, vital signs, electrocardiograms, clinical laboratory testing, pregnancy testing where applicable, hypertrichosis evaluations, and monitoring of adverse events and concomitant medications throughout the study. Efficacy and safety outcomes will be compared across all treatment groups.

Efficacy and safety data will be analyzed according to a predefined Statistical Analysis Plan established before database lock.

03

Conditions studied

  • Androgenetic Alopecia
  • Female Pattern Baldness

Browse trials for

Keywords

  • Androgenetic alopecia
  • Female Pattern Baldness
  • FAGA
  • Minoxidil
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients aged 18 years or older, with general good health (i.e., with no history of cardiovascular disorders, or any other disease).
  2. Diagnosed with FAGA, based on a discernible decrease in hair density (Sinclair Scale 2-4) in the centroparietal area of the scalp.
  3. Hair color of patient provides sufficient contrast with the scalp and as confirmed by TrichoLab Virtual Tattoo® technology at Screening/Visit 1.
  4. A personally signed and dated document indicating that the patient, has been informed of all pertinent aspects of the clinical trial.
  5. Negative serum pregnancy test at Visit 1/Screening and negative urine pregnancy test at Visit 2/Baseline for women of (WOCBP).
  6. WOCBP must either be permanently sterile1 or agree to use a highly effective method (failure rate ˂1% per year when used consistently and correctly) throughout the clinical trial and for at least 2 weeks after last administration of IPs.

    Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2/Baseline and if used as contraceptive and planned to be continued throughout the clinical trial duration.

  7. Patients willing to maintain the same hairstyle (color and hair regimen) throughout the clinical trial. Hair length must remain of sufficient length to not affect determination of hair density and patient should discuss with clinical trial personnel before changing from Visit 2/Baseline.
  8. Patient is willing to maintain the same depilatory habits and intervals regarding facial or body hair before each visit throughout duration of the clinical trial.
  9. Patient is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical trial procedures, including daily e diary recordings by the patient using an own electronic device (e.g., tablet, smartphone, personal computer) and an internet connection during the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Known or known allergy to minoxidil or to any of the other components of the products.
  2. Pregnancy or pregnancy desire during the clinical trial.
  3. Breastfeeding/Nursing women.
  4. Any diagnosed treated or untreated hypertension (or blood pressure values >150 mmHg systolic / >95 mmHg diastolic) as determined at Visit 1/Screening, and/or history/signs of known cardiovascular diseases (including but not limited to cardiac ischemia, congestive heart failure, cardiac arrhythmia), and patients with pathologies or punctual situations that might either be caused by or increase the risk of cardiac disorders.
  5. Patients with any dermatological disorders of the scalp in the target region at Visit 1/Screening with the possibility of interfering with the application of the IPs or examination method, such as

    1. Active moderate or severe seborrheic dermatitis under chronic treatment, abrasion, actinic keratosis, or inflammatory disorders, or
    2. any local infection of the skin/subcutaneous tissues of the head within the previous 3 months, or
    3. any documented history of active atopic dermatitis or psoriasis in the scalp within the previous 6 months.
    4. any other types of alopecia (e.g., alopecia areata or scarring alopecia) at any time point or diffuse telogen effluvium, trichotillomania, or other pathological hair loss conditions/diseases other than AGA in the last 3 months at the discretion of the investigator).
  6. Patients who had hair transplant surgery at any time.
  7. Patients who had hair weaving, or any other hair extension methods within the last 6 months prior to Visit 2/Baseline.
  8. abnormal laboratory values or findings (if applicable) at Visit 1/Screening indicative of physical illness, according to investigator assessment.
  9. Both creatinine and above at Visit 1/Screening.
  10. Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases that in the opinion of the investigator may interfere with the aim of the clinical trial.
  11. Patient has used any of the following topical preparations or procedures on the scalp:

    1. Topical scalp treatments for hair growth, including minoxidil within the last 6 months prior to Visit 2/Baseline; or hormone therapy, antiandrogens, or other agents that are known to affect hair growth within 12 weeks prior to Visit 2/Baseline.
    2. Topical scalp treatments that might have had ancillary effect on hair growth including, but not limited to, , pimecrolimus, and tacrolimus within the last 4 weeks prior to Visit 2/Baseline.
    3. Topical scalp over the counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Maxilene®, Nioxin®, Foltene®, etc.) or hair health or hair growth products with saw palmetto, copper, etc. within the last 4 weeks prior to Visit 2/Baseline.
    4. Light or laser treatment or microneedling of scalp within the last 6 months prior to Visit 2/Baseline.
    5. rich plasma (PRP) procedure on the scalp within the last 6 months prior to Visit 2/Baseline.
  12. Patient has used the following systemic medications or procedures:

    1. Zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine, benoxaprofen, tamoxifen, phenothiazines, or other vasodilators or antihypertensive agents such as guanethidine and derivatives within the last 12 months prior to Visit 2/Baseline.
    2. Any 5 alpha reductase medications (i.e., dutasteride, finasteride [Propecia®, etc.] or similar product[s]) within the last 12 months prior to Visit 2/Baseline.
    3. Retinoid therapy within the last 6 months prior to Visit 2/Baseline.
    4. Beta blockers, anabolic steroids, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2/Baseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable (defined as doses and frequency unchanged for at least 4 weeks prior to Visit 2/Baseline.
    5. Drugs with antiandrogenic properties, such as flutamide, cimetidine, or ketoconazole within the last 6 months prior to Visit 2/Baseline; bicalutamide within 2 months and spironolactone within 1 month prior to Visit 2/Baseline. Gestagens with antiandrogen properties (e.g., cyproterone acetate, dienogest) are allowed if treatment is stable since the last 6 months prior to Visit 2/Baseline and if used as .
    6. Minoxidil within the last 6 months prior to Visit 2/Baseline.
    7. Prostaglandins and derivates within the last 3 months prior to Visit 2/Baseline. Topical and ocular prostaglandins and its derivates are allowed.
    8. Biotin (>5 mg) within the last 4 weeks prior to Visit 2/Baseline.
    9. Previous radiation of the scalp and treatment with chemotherapy/systemic cytotoxic agents at any timepoint.
  13. Participation in the evaluation of any drugs within 30 days or 5 half lives (whichever is longer) prior to Visit 2/Baseline, calculated from the first day of the month following the last visit of the previous clinical trial.
  14. History of drug and alcohol dependency.
  15. In the opinion of the investigator the patient should not participate in the clinical trial, e.g., due to probable non compliance or inability to understand the clinical trial and give adequately .
  16. Close affiliation with the investigator (e.g., a close relative) or persons working at the clinical trial centers or patient is an employee of sponsor.
  17. Patient is institutionalized because of legal or regulatory order.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Active group

    Oral minoxidil 1 mg (1 tablet, OD) + topical vehicle solution (1 ml, BID)

    Drug: Minoxidil Tablets · Drug: Vehicle solution

  • Active comparator
    Control group

    Oral placebo (1 tablet, OD) + topical 2% Minoxidil solution (1 ml, BID)

    Drug: Minoxidil Topical · Drug: Placebo oral tablet

  • Placebo comparator
    Placebo group

    oral placebo (1 tablet, OD) + topical vehicle solution (1 ml, BID)

    Drug: Placebo oral tablet · Drug: Vehicle solution

Interventions

  • The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

  • DrugMinoxidil Topical

    The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

  • DrugPlacebo oral tablet

    The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

  • DrugVehicle solution

    The clinical trial will use a block randomization scheme to assign those eligible patients to one of the three arms of the study treatment on a 2:2:1 ratio. All patients will be given a kit with oral tablets (active/placebo) 1 tablet to be taken once a day and a topical solution (active comparator/vehicle) to be applied 1 ml twice daily.

06

What researchers measure

Primary outcomes

  1. Change in Target Area non vellus Hair Counts (TAHC)

    This is the change in TAHC from Baseline to Week 24 (6 months). A descriptive analysis of the TAHC score at Baseline and Week 24 will be performed by treatment group (active, control and placebo). Also, a descriptive analysis of the change from Baseline to Week 24 (Week 24 - Baseline) will be performed by treatment group (active, control and placebo).

    Time frame: From baseline to week 24

07

Study locations

27 sites
  • Fachklinik Bad Bentheim Klinisches Studienzentrum
    Bad Bentheim, Germany
  • CRC - Charité Universitätsmedizin Berlin Clinical Research Center for Hair and Skin Science
    Berlin, Germany
  • emovis by Futuremeds GmbH
    Berlin, Germany
  • Klinische Forschung Berlin Mitte GmbH
    Berlin, Germany
  • Hautzentrum im Jahrhunderthaus
    Bochum, Germany
  • Rosenpark Reasearch GmbH
    Darmstadt, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, Germany
  • Privatpraxis Dr. Hilton & Partner
    Düsseldorf, Germany
  • Klinik für Dermatologie, Venerologie und Allergologie - Universitätsmedizin Frankfurt
    Frankfurt, Germany
  • Dermaticum - Privatpraxis für Dermatologie
    Freiburg im Breisgau, Germany
  • Eurofins bioskin - Research Center Dermatology
    Hamburg, Germany
  • Klinische Forschung Hamburg GmbH
    Hamburg, Germany
  • Klinische Forschung Hannover Mitte GmbH
    Hanover, Germany
  • Klinische Forschung Karlsruhe GmbH
    Karlsruhe, Germany
  • Siteworks - Zentrum für klinische Studien Karslruhe
    Karlsruhe, Germany
  • Siteworks - Prüfzentrum Lohne
    Löhne, Germany
  • Haut-und Lasercentrum - Dr. Tanja Fischer und Kollegen
    Potsdam, Germany
  • SGS proderm GmbH
    Schenefeld, Germany
  • Klinische Forschung Schwerin Gmb
    Schwerin, Germany
  • TRIDERM Study Site Dermatological practice Dr. Leitz and colleagues
    Stuttgart, Germany
  • Università Sapienza di Roma Dipartimento di Scienze Cliniche Internistiche Anestesiologiche e Cardiovascolari U.O.C. di Dermatologia Centro per lo studio sulla fisiopatologia degli Annessi Cutanei Sapienza Università di Roma
    Roma, Italy
  • Hospital CUF Descobertas - Ensaios Clínicos
    Lisbon, Portugal
  • Personal Derma - Clínica Dermatológica & Estética
    Lisbon, Portugal
  • Instituto Dermatológico da Madeira - Dermatologia e Laserterapia
    Madeirã, Portugal
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Clínica Grupo Pedro Jaén
    Madrid, Spain
  • Institut Medico Ricart (IMR)
    Valencia, Spain
08

References and documents

Publications

  • Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, Lobo R, Olsen E. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2875-2891. doi: 10.1210/jc.2018-02548. PubMed 30785992 ↗
  • Russo PM, Fino E, Mancini C, Mazzetti M, Starace M, Piraccini BM. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):608-611. doi: 10.1111/jdv.15327. Epub 2018 Dec 2. PubMed 30394586 ↗
  • Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001 Sep;45(3 Suppl):S70-80. doi: 10.1067/mjd.2001.117426. No abstract available. PubMed 11511856 ↗
  • Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol. 2015 Oct;73(4):705-6. doi: 10.1016/j.jaad.2015.06.063. No abstract available. PubMed 26369846 ↗
  • Starace M, Orlando G, Alessandrini A, Piraccini BM. Female Androgenetic Alopecia: An Update on Diagnosis and Management. Am J Clin Dermatol. 2020 Feb;21(1):69-84. doi: 10.1007/s40257-019-00479-x. PubMed 31677111 ↗
  • Redler S, Messenger AG, Betz RC. Genetics and other factors in the aetiology of female pattern hair loss. Exp Dermatol. 2017 Jun;26(6):510-517. doi: 10.1111/exd.13373. PubMed 28453904 ↗
  • Ramos PM, Brianezi G, Martins AC, da Silva MG, Marques ME, Miot HA. Apoptosis in follicles of individuals with female pattern hair loss is associated with perifollicular microinflammation. Int J Cosmet Sci. 2016 Dec;38(6):651-654. doi: 10.1111/ics.12341. Epub 2016 Jun 1. PubMed 27163333 ↗
  • Vano-Galvan S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones OM, Saceda-Corralo D, Rodrigues-Barata R, Jimenez-Cauhe J, Koh WL, Poa JE, Jerjen R, Trindade de Carvalho L, John JM, Salas-Callo CI, Vincenzi C, Yin L, Lo-Sicco K, Waskiel-Burnat A, Starace M, Zamorano JL, Jaen-Olasolo P, Piraccini BM, Rudnicka L, Shapiro J, Tosti A, Sinclair R, Bhoyrul B. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021 Jun;84(6):1644-1651. doi: 10.1016/j.jaad.2021.02.054. Epub 2021 Feb 24. PubMed 33639244 ↗
  • Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008 Jun;22(6):1725-36. doi: 10.1096/fj.07-099424. Epub 2008 Feb 7. PubMed 18258787 ↗
  • Burton JL, Marshall A. Hypertrichosis due to minoxidil. Br J Dermatol. 1979 Nov;101(5):593-5. PubMed 518830 ↗
  • Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med. 1980 Dec 18;303(25):1480-1. doi: 10.1056/nejm198012183032516. No abstract available. PubMed 7432414 ↗
  • Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Moreno-Arrones OM, Ortega-Quijano D, Fernandez-Nieto D, Jaen-Olasolo P, Vano-Galvan S. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. Dermatol Ther. 2020 Nov;33(6):e14106. doi: 10.1111/dth.14106. Epub 2020 Sep 7. PubMed 32757405 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 5, 2023
StartActual
Oct 17, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Nov 16, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05888922
Lead sponsor
Industrial Farmacéutica Cantabria, S.A.
Collaborators
Bioskin GmbH, Astrum CRO, S.L.
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
Oct 17, 2024
Primary completion
Oct 2026 (estimated)
Completion
Nov 16, 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Ana López-Ballesteros
study director · Industrial Farmacéutica Cantabria, S.A.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion